Intratumoral injection of OK432 and lymphokine-activated killer activity in peripheral blood of patients with hepatocellular carcinoma |
| |
| Institution: | 1. Department of Internal Medicine, Radboud University Medical Centre, Nijmegen 6525 GA, the Netherlands;2. Murdoch Children’s Research Institute, The Royal Children’s Hospital, Parkville, VIC 3052, Australia;3. Division of Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, University Children`s Hospital Bern, Inselspital, Bern 3010, Switzerland;4. Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland;5. Department of Endocrinology, The Royal Children`s Hospital, Parkville, VIC 3052, Australia;6. Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia;7. Department of Neurodevelopment and Disability, Royal Children’s Hospital, Parkville, VIC 3052, Australia;8. Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3052, Australia;9. Department of Medicine, University of Turku, 20500 Turku, Finland;10. Division of Medicine, Turku University Hospital, 20500 Turku, Finland;11. Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany;12. Department of Pediatrics, Monash University, Clayton, VIC 3168, Australia;1. Université de Toulouse, Inserm, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, 31100 Toulouse, France;2. Sanofi, Large Molecule Research, 94400 Vitry-sur-Seine, France;1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;2. Aravive Biologics, Inc, Houston, TX, USA;3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
| |
| Abstract: | Lymphokine-activated killer (LAK) activity of peripheral blood mononuclear cells (PBMC) from 33 patients with hepatocellular carcinoma was significantly decreased compared with that of healthy volunteers. There was less LAK activity in PBMC from patients with larger tumours (5 cm or more in diameter) than in patients with smaller tumours (under 5 cm in diameter). In 8 out of 20 patients with larger tumours there was none or little LAK activity. Flow cytometry revealed that the percentage of Leu11b+ cells in PBMC was lower in patients than in normal volunteers, and was lowest in patients with larger tumours. 10 patients with hepatocellular carcinoma were treated with intratumoral injection of OK432. LAK activity was enhanced after treatment in 7 cases, and the percentage of Leu11b+ cells was increased. Enhancement of LAK activity in response to OK432 was more significant in patients with smaller rather than larger tumours. Of the 7 high LAK responders, 4 showed 50–100% tumour regression at 6–9 weeks after injection. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
